Tue, May 6, 9:12 PM (6 days ago)
**Ginkgo Bioworks Holdings, Inc. (DNA) Q1 2025 Financial Summary** **Financial Health & Performance:** - **Revenue:** $48.3 million (up 27% YoY) driven by $7.5 million non-cash revenue from BiomEdit contract termination. - **Profit Margins:** Negative, with a net loss of $90.96 million (improved from $165.91 million loss in Q1 2024). - **Cash Flow:** Negative operating cash flow of $51.52 million, primarily due to restructuring charges and investments. - **Earnings Changes:** Improved earnings with a loss of $1.68 per share (vs. $3.31 loss in Q1 2024). **Segment Performance:** - **Cell Engineering:** Revenue up 37% YoY to $38.23 million, driven by non-cash revenue and new offerings. - **Biosecurity:** Revenue stable at $10.09 million, with cost reductions implemented. **Trends & Uncertainties:** - **Restructuring:** Ongoing, with $5.3 million in charges in Q1 2025. Expected to complete in 2025. - **Investments:** $191.2 million in marketable debt securities and $7.6 million in property and equipment. - **Market Risks:** Interest rate and foreign currency exchange rate risks managed, with no material impact expected. **Future Operations:** - Focus on R&D, Foundry and Codebase enhancements, and new offerings. - Potential acquisitions and integration of companies, assets, or intellectual property. - Continued restructuring actions and cost management. **Impact:** - Improved financial performance YoY, with significant non-cash revenue impact. - Continued investments in growth and restructuring efforts. - Management remains optimistic about long-term prospects despite short-term challenges.